Known as the prostate cancer powerhouse treatment Zytiga, Abiraterone Acetate has recently become a sales powerhouse for Medivation. The reason for the hype centers on a new indication for this potent anti-cancer drug, specifically as an efficacious pre-chemo treatment. Initial FDA approval for Abiraterone was for post-chemotherapy only. As a post-chemo treatment Zytiga was by[…]
Abiraterone Acetate Soars with Pre-Chemotherapy Indication
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, New Indication Approval Tags: Docetaxelprostate cancer Feb 02, 2015
Enzalutamide Provides Profit and Hope
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: 114977-28-5Docetaxelprostate cancer Sep 11, 2013
Patients with late-stage prostate cancer stand to benefit greatly since the approval of Enzalutamide, CAS number 915087-33-1. Sales of the brand name of Enzalutamide, Xtandi, have recently proven to garnish sizable profits for Medivation, the biopharmaceutical parent of this wonder drug. The launch of Enzalutamide in Europe and Asia in upcoming months are projected to[…]
Cabazitaxel Adds Time and Hope to Prostate Cancer Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2010 Tags: prostate cancer Dec 28, 2012
Cabazitaxel was approved by the FDA in 2010 as the brand name Jetvana, for the treatment of advanced prostate cancer. Cabazitaxel, CAS number 183133-96-2, is an anti-cancer medication that is typically prescribed alongside the steroid prednisone. Patients that have become resistant to docetaxel or other cancer treatments may find success with cabazitaxel. Adverse effects are[…]
Triptorelin Acetate is Effective On and Off Label
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2015 Tags: prostate cancer Nov 12, 2012
Used to treat the symptoms of prostate cancer, Triptorelin Acetate CAS# 149194-24-7 is a man-made form of a hormone that regulates many functions in the body. Triptorelin is effectual at over stimulating the body’s own production of these specific hormones, therefore causing the production of these hormones to shut down. This shut down is triggered[…]
Fight Fungal Infections and Prostate Cancer with Itraconazole
Anti-Fungal, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015 Tags: prostate cancer Sep 25, 2012
Itraconazole is an azole antifungal medicine. Known as the brand name Sporanox, which is marketed Janssen, the patent for this potent product expires on January 13, 2015. Itraconazole works by interfering with the formation of the fungal cell membrane. It is a formidable product for treating infections caused by fungus, which can invade any part[…]
Denosumab is Poised to be a Boon to Bone Health
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: breast cancermultiple myelomaosteoporosisprostate cancer Mar 14, 2012
Denosumab, CAS number 615258-40-7, offers divergent options for researchers working with this monoclonal antibody. The scope of efficacy for denosumab is wide, with one of it’s uses being an approved treatment of osteoporosis in women, particularly those women who are post menopausal. Known as the brand Prolia®, which is marketed by Amgen, denosumab is effectively[…]
Toremifene in the prevention and treatment of prostate cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: breast cancerprostate cancer Jun 03, 2011
Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to[…]
FDA Denied Dutasteride Specific Use, But Existing Approval OK
Drug Research & Development API Tags: GlaxoSmithKlineprostate cancer Jan 27, 2011
On Wednesday January 26, 2011, GlaxoSmithKline (GSK) announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (Dutasteride CAS# 164656-23-9 available for R&D purposes from LGM Pharma, a US based API supplier) for reducing the risk of prostate[…]
